Selumetinib ≥95%

Supplier: ADIPOGEN CORP MS

Synonyms: 5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide, AZD6244

SYN-1016-M001 SYN-1016-M005 SYN-1016-M010 SYN-1016-M050
102991-368EA 119.08 USD
102991-368 102991-370 102991-372 102991-374
Selumetinib ≥95%
Selumetinib

Selumetinib (AZD6244) is a second-generation, orally available, potent and selective ATP non-competitive inhibitor of MEK 1/2. In direct assays, AZD6244 selectively inhibits purified active MEK1 and MEK2 with an IC(50) of 14nM, and AZD6244 has reported IC(50) values of 100nm for MEK1 in ELISA assays and in bindings assays against recombinant domains of MEK2, Kd values were 53nM for AZD6244. AZD6244 demonstrated very effective anti-proliferation effects against several different cell lines with IC(50) values ranging from a low of 3nM to 1µM depending upon the cell system used, and the compound inhibits basal and growth factor-stimulated phosphorylation of ERK1/ 2 with IC(50) concentrations 40nM. AZD6244 has demonstrated potent dose-dependent antitumor activity against a panel of mouse xenograft models of colorectal, pancreatic, liver, skin, and lung cancer, and inhibition of tumor growth was found to correlate with the reduction of phospho-ERK1/2 levels in tumors.

Formula: C₁₇H₁₅BrClFN₄O₃
MW: 457.7 g/mol
Storage Temperature: Freezer
MDL Number: MFCD11977472
CAS Number: 606143-52-6

Order Now

Specification Test Results

Purity 95%
Appearance/Color Solid.
Solubility Soluble in DMSO. Slightly soluble (1mg/ml) in ethanol.

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR